

Bod awarded US Hemp Authority certificate for CBD extract and CBD products

- Certification awarded by the US Hemp Authority for Bod's exclusive CBD extract and related products under CBII, H&H CBD brand
- Bod currently sells a range of CBD products in the US through its established CBII brand and via exclusive global partner Health & Happiness Group Limited ("H&H", HKSE: 1112)
- The US Hemp Authority is an independent self-regulatory organisation focused on ensuring the US industry maintains the highest standards and best practices to ensure consumer confidence
- Certification adds to the growing list of regulatory recognition for Bod's extract which includes Novel Food Application validation in the UK and Generally Recognised as Safe Status in the US
- Recognition follows stringent lab testing, quality and audits of all information associated with Bod's CBD extract and products
- Certification provides Bod with another competitive advantage in the US, additional validation of its extract and product development initiatives and can assist brand awareness amongst consumers

Sydney, Australia – 19 August 2022: Cannabis focused drug development and product innovation company Bod Australia Limited ("Bod" or "the Group") (ASX: BOD) is pleased to advise it has been awarded US Hemp Authority Certification for its exclusive CBD extract and its CBD products sold in the US.

Bod currently sells a range of CBD wellness products in America through its established CBII brand (us.cbii-cbd.com/shop/cbd-oil) and through exclusive global partner and Swisse Vitamins parent company Health and Happiness Group Limited ("H&H", HKSE: 1112).

Bod was granted the certification by the US Hemp Authority, which is an independent self-regulatory organisation for the domestic hemp and CBD industry. The US Hemp Authority Certification Program is the hemp industry's initiative to provide the highest standards, best practices and self-regulation to underpin consumer and retailer confidence in hemp and CBD products.

The process was undertaken over a 12 month period and included verification processes around the Company's CBD extract, stringent lab testing of Bod's extract and products for multiple contaminants and THC limits, as well as ensuring the Company's operations do not utilise synthetic cannabinoids, undertake correct labelling practises and batches are traceable back to original hemp plant material. These tests were undertaken by a third-party to ensure independence.

The certification adds to the Company's ongoing regulatory recognition and follows Bod's Novel Food Application in the UK (refer ASX announcement: 21 February 2022) and Generally Recognised as Safe ("GRAS") status, in line with US the stringent US Food and Drug Administration ("FDA") safety guidelines (refer ASX announcement: 23 September 2020).

Further, the certification provides another third party endorsement for the Company, its CBD extract and products, adds another competitive advantage in the US, has the potential to increase brand recognition amongst key customers and provides Bod with another intellectual property asset to leverage and drive revenue streams.

CEO Ms Jo Patterson said: *"Being awarded US Hemp Authority Certification follows a long and stringent testing process, undertaken on all facets of Bod's extract and products by a third party. To have passed this process validates the superior quality of the Company's extract, operations and product development initiatives."*

"Having been awarded the certification adds to the growing list of regulatory recognition for Bod's extract which has already been validated both the UK and the US. Further, we anticipate that the US Hemp Authority's seal of approval will provide consumers with added confidence in the Company's products."

CONTACT

T +61 2 9199 5018 E info@bodaustralia.com bodaustralia.com

This announcement has been approved by the Board of Bod Australia Limited.

-ENDS-

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538